Heather Wakelee, MD, discusses the results of the AVAPERL trial.
Heather Wakelee, MD, an assistant professor at the Stanford University School of Medicine and member of the Stanford Cancer Institute, discusses the results of the AVAPERL trial.
In the AVAPERL trial, patients with non-small cell lung cancer were treated with cisplatin, pemetrexed, and bevacizumab, Wakelee says. The non-progressing patients were then randomly selected to either stay on bevacizumab alone or receive pemetrexed and bevacizumab.
Wakelee says the trial showed a striking improvement of progression-free survival for the patients who received both pemetrexed and bevacizumab. In the final overall survival analysis, there was a numeric advantage to the two-drug regimen, Wakelee says, but it was not statistically significant.
Wakelee interprets the data to mean that the two-drug regimen is more active, but she questions if the increased toxicity is worth it for every patient.
Clinical Pearls
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More